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ABSTRACT
Objective To improve the prenatal diagnosis of thanatophoric dysplasia by deﬁning the change in fetal size across
gestation and the frequency of sonographic features, and developing non-invasive molecular genetic diagnosis based
on cell-free fetal DNA (cffDNA) in maternal plasma.
Methods Fetuses with a conﬁrmed diagnosis of thanatophoric dysplasia were ascertained, records reviewed,
sonographic features and measurements determined. Charts of fetal size were then constructed using the LMS
(lambda-mu-sigma) method and compared with charts used in normal pregnancies and those complicated by
achondroplasia. Cases in this cohort referred to our Regional Genetics Laboratory for molecular diagnosis using
cffDNA were identiﬁed and results reviewed.
Results Forty-two cases were scanned in our units. Commonly reported sonographic features were very short and
sometimes bowed femora, frontal bossing, cloverleaf skull, short ﬁngers, a small chest and polyhydramnios. Limb
shortening was obvious from as early as 13 weeks’ gestation, with minimal growth after 20weeks. Analysis of
cffDNA in three of these pregnancies conﬁrmed the presence of the c.742C>CT (p.Arg248Cys) or the c.1948A>AG
(p.Lys650Glu) mutation in the ﬁbroblast growth factor receptor 3 gene.
Conclusion These data should improve the accuracy of the sonographic diagnosis of thanatophoric dysplasia and
have implications for reliable and safe targeted molecular conﬁrmation using cffDNA. © 2013 The Authors. Prenatal
Diagnosis published by John Wiley & Sons Ltd.
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INTRODUCTION
Thanatophoric dysplasia (TD) is the most common lethal
dominant skeletal dysplasia with an incidence of 2–3 per
100000 births.1 It results fromamutation in theﬁbroblast growth
factor receptor 3 (FGFR3) gene located on 4p16.3.2,3 There are
several mutations known to cause TD, the most common being
Arg248Cys, Tyr373Cys and Lys650Glu.3 TD may be divided into
subtypes I and II, based both on molecular diagnosis and on
clinical features, but there is considerable overlap between
the two groups. Cases with a Lys650Glu mutation have
predominantly milder radiological and histological features with
straight femora and craniosynostosis and have been classiﬁed as
Type II. In Type I, femora tend to be curved and craniosynostosis
infrequent,3 resulting most commonly from the Arg248Cys or
Tyr373Cys substitutions. Prenatal sonographic detection occurs
traditionally in the second trimester, at the time of the routine
anomaly scan when the fetus is found to have short long bones,
a small chest, macrocephaly, frontal bossing, short ﬁngers,
cloverleaf skull or telephone receiver-shaped femora (Figure 1),
but with increasing use of ﬁrst trimester ultrasound, these
features are increasingly detected earlier in pregnancy.4 The
accuracy of prenatal diagnosis of TD based on ultrasound
ﬁndings has been reported to vary from 40% to 88%.5–10
Accurate sonographic diagnosis allows for targeted molecular
testing that, until recently, required analysis of fetal cells obtained
following an invasive diagnostic test such as amniocentesis or
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chorionic villus sampling.11 Identiﬁcation of cell-free fetal DNA
(cffDNA) circulating in maternal plasma12 has allowed for the
development of safer, non-invasive genetic prenatal diagnosis
that relies on a maternal blood sample.13
The objectives of this study were to improve the prenatal
diagnosis of TD by constructing fetal size charts for fetuses with
TD, deﬁning the frequency of other associated sonographic
features in order to highlight differences with other dysplasias
and to explore the possibility of developing targeted molecular
analysis using cffDNA for deﬁnitive prenatal diagnosis.
MATERIALS AND METHODS
Development of fetal size charts and ascertainment of
sonographic features
Our fetal medicine unit databases were searched from 1992 to
2011 for all fetuses that presented prenatally with short limbs
where TD was the aetiology. Only those with a diagnosis
conﬁrmed either by the presence of an FGFR3 gene mutation
or by post-mortem radiology were included. Prenatal records
were examined to ascertain all fetal measurements and other
sonographic features. This was part of a retrospective audit of
cases, and local approvals were not required.
A search of PubMed, Web of Science and EMBASE was
made to identify previous citations in the English literature
reporting sonographic ﬁndings in fetuses with TD. We used
MeSH (medical subject heading) terms and key words related
to TD and prenatal ultrasound, including ‘thanatophoric
dysplasia’, ‘ultrasound’, ‘prenatal’, ‘sonography’, ‘skeletal
dysplasia’, ‘limb shortening’, ‘macrocephaly’, ‘telephone-
receiver femur’, ‘cloverleaf skull’, ‘lethal’ and ‘chondrodysplastic
dwarﬁsm’. Studies where data on the prenatal sonographic
ﬁndings in TD could be identiﬁed were included.
Construction of fetal size charts
Using data obtained fromour owncohort of cases,we constructed
charts of fetal size for head circumference (HC), abdominal
circumference (AC) and long bones using the LMS (lambda-mu-
sigma) method.14 This method models the age-changing
distribution of the measurement in terms of the median and
coefﬁcient of variation after applying a suitable Box–Cox power
transformation. Here, the medians were ﬁtted as smooth curves,
whereas the coefﬁcients of variation all decreased linearly with
increasing gestation. The distributions of all threemeasurements
were skewed, requiring Box–Cox transformations of power0.5,
3.7 and3.9 for femur length (FL), AC and HC, respectively. The
data derived were also compared with charts recommended for
routine assessment of fetal size in the UK,15–17 both as centile
plots and Z-score plots relative to these normal ranges. In
addition, the femur length charts were compared with those
derived for fetuses with achondroplasia.18
Development of non-invasive prenatal diagnosis of TD using
cffDNA
Three women in this series hadmaternal blood taken for analysis
of cffDNA. All cases had blood taken prior to invasive procedures
or termination of pregnancy. In two cases, blood was taken and
plasma stored as part of an ongoing study to develop non-
invasive prenatal diagnosis (NIPD) using cffDNA.19 In the third
affected pregnancy, bloodwas taken prospectively and the results
used to conﬁrm the sonographic diagnosis prior to termination of
pregnancy. The diagnosis was also conﬁrmed by molecular
analysis of skin cells after delivery. This woman also had blood
taken in a second pregnancy, whichwas not affected and resulted
in the birth of a normal baby. In all cases, plasma was separated
from the blood cells by centrifugation at 1500 g for 10min. The
supernatant was then transferred to fresh tubes, ensuring that
the buffy coat remained intact. The plasma was then centrifuged
at 16000 g for 10min to remove any remaining cells and analysed
immediately or transferred into 2mL Lo-Bind tubes (Eppendorf,
Hamburg, Germany) and stored at 80 C until DNA extraction.
DNA extraction
DNA was extracted from 5mL of plasma using the QIAamp
Circulating Nucleic Acid kit (Qiagen, Hilden, Germany) according
tomanufacturer’s instructions and was eluted into a ﬁnal volume
of 75mL AVE elution buffer.
Figure 1 Sonographic features of thanatophoric dysplasia (TD) with a view of the thorax demonstrating short ribs (A), a view of the head in a
fetus with TD II and a cloverleaf skull (B), a longitudinal view of the thorax and abdomen demonstrating the ‘champagne cork’ appearance due
to the very small chest (C), a 3-D image of the femur demonstrating slight bowing (D), a 3-D view of the face (E), a sagittal view showing the
frontal bossing (F) also demonstrating a very small chest and a view of a hand illustrating the short ﬁngers (G)
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PCR from cffDNA
Primer sequences are detailed in Table 1. The primers TDIF and
TDIR were used to amplify the segment of DNA that contains
nucleotide c.742. Two sets of primers, namely TDIIF1 and
TDIIR1, and TDIIF2 and TDIIR2, were used to amplify the
segment of DNA containing nucleotide c.1948. Five microlitres
of plasma DNA or 50ng of gDNAwas used as a template for each
PCR, in a mix containing 1 PCR Buffer II, 3mLMgCl2, 200mMof
each dNTP, 10pmol of each primer and 0.25mL Amplitaq Gold in
a ﬁnal volume of 50mL. Cycling conditions were as follows: after
an initial incubation at 95 C for 5min, the reaction was cycled
for 10 cycles at 95 C for 15 s, 65 C for 15 s (decreasing in
temperature by 1 C per cycle) and 72 C for 30 s, followed by
40 cycles at 95 C for 15 s, 55 C for 15 s and 72 C for 30 s.
Restriction enzyme analysis
For screening of samples for c.1948G>A mutation, 5U of BbsI
enzyme (New England Biolabs, Ipswich, MA, USA) was used to
digest 25mL of PCR product at 37 C for 2h. For detection of the
c.742>T transition, 10U of AfeI, BsiHKAI or DraIII enzymes was
used to digest 25mL of DNA at either 37 C (AfeI and DraIII) or
65 C (BsiHKAI) for 2h. Digests were run on a 3% polyacrylamide
gel and visualised with ethidium bromide. For the case where the
mutation analysis was negative, theRASSF1A assay,20 asmodiﬁed
for use in clinical practice,21 or the SRY assay was used to conﬁrm
the presence of cffDNA.
Table 1 Primer sequences used in the analysis of cell-free fetal
DNA
Primer name Sequence (50–30) Amplicon size (bp)
TDIF CTGAGCGTCATCTGCCCC 127
TDIR TGCGTCACTGTACACCTTGC
TDIIF1 CGTGCACAACCTCGACTACTAC 120
TDIIR1 CTGGGAGGGTGTGGGAAG
TDIIF2 ACGTGATGAAGATCGCAGACT 125
TDIIR2 AGGCGTCCTACTGGCATGA
Figure 2 Fetal size charts for femur length (a), head circumference (b) and abdominal circumference (c) against gestational age in fetuses with
thanatophoric dysplasia. Note the curvature in the femur length chart as growth declines signiﬁcantly from 20weeks gestation. Comparison
with normal fetuses is demonstrated by overlaying measurements from affected fetuses on charts of fetuses of normal size (d–f, respectively)
(derived from Chitty et al.15–17) and by plots of Z-scores showing the deviation from the normal range (g–i, respectively)
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RESULTS
Sonographic ﬁndings in TD
Forty-two cases with a conﬁrmed diagnosis of TD had been
scanned in our units. Presentation was between 13 and
32weeks. In six cases, serial measurements were available.
Charts were constructed using all available measurements
treated cross-sectionally. Those for the head, AC and femur
length are shown in Figure 2. Measurements of FL lay below
the normal range from early in pregnancy (Figure 2d) with
the difference between normal and TD femur length
increasing with gestation (Figure 2g). The medians plotted
against gestation were slightly curved for FL (Figure 2a) from
around 20weeks’ gestation, after which time there was poor
femur growth overall (Figure 2a and d). The fetal size
charts for other long bones followed a similar pattern. The
shapes of the HC (Figure 2b) and AC (Figure 2c) charts both
followed the normal pattern (Figure 2e and f), although the
HC tended to be greater in TD fetuses across gestation. Z-
score plots (Figure 2g) comparing cases with the normal
ranges15–17 show that the FL lies below the normal range for
all except two cases. Both of these measurements were made
at or before 14weeks’ gestation. By contrast,Z-plots conﬁrm that
the HC tends to be greater than normal across gestation
(Figure 2h).
Figure 3 shows the comparison of the femur length
measurements in this cohort of fetuses with TD with a
previously reported cohort of fetuses with achondroplasia.18
This demonstrates discrimination of femur length in these
two conditions, with those of TD fetuses falling below those
with achondroplasia at all gestations with the exception of
one fetus with achondroplasia.
The reports describing additional ultrasound ﬁndings were
available for all 42 of our cases (Table 2). A diagnosis of TD
was suspected in 36 cases based on the sonographic features
(Figure 1). In the other six cases, a diagnosis of a serious
skeletal dysplasia was made, but no diagnosis was speciﬁed.
Figure 3 Comparison of femur length in fetuses with thanatophoric
dysplasia (closed circle) or achondroplasia (open circle) with normal
fetuses (derived from Chitty et al.18) showing the distinctive pattern for
TD, with little increase in size from the mid second trimester and
achondroplasia, which follows the normal femoral centiles until around
25weeks’ gestation when it then falls away from the normal centiles
Table 2 Summary of the sonographic features reported in fetuses with thanatophoric dysplasia including the frequency of ﬁndings in
the cases reported in this study
Sonographic
ﬁnding Our cases
Reports describing
1–3 cases Chen et al.22 Tsai et al.23
Schramm
et al.5
Overall
frequencya
Overall
frequencya (%)
Total cases 42 40 4 9 40
Gestational age (weeks) 13–32 11–30 18–31 20–34 16–35
Increased nuchal translucency 2/3 6/7 8/10 80
Bowed femur 28/42 29/40 1/4 9/9 67/95 70
Short femur 42/42 40/40 4/4 9/9 40/40 137/137 100
Macrocephaly 23/39 15/17 1/4 6/9 20/38 65/107 61
Cloverleaf skull 13/42 11/40 1/4 24/86 30
Narrow thorax 35/37 38/38 4/4 9/9 37/40 123/128 96
Frontal bossing 24/30 6/8 4/4 9/9 43/51 84
Short ﬁngers/trident hand 16/31 16/31 52
Increased AF 11/35 10/12 6/9 27/46 59
Other features:
Ventriculomegaly 4 5
ACC 1
Talipes 2 3
Redundant skinfolds 3
AF, amniotic ﬂuid; ACC, absence of the corpus callosum.
aFrequency only includes cases where there was evidence in the paper or, for our cases, the ultrasound report that a particular feature was examined.
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In 13, the diagnosis was conﬁrmed following invasive testing
and molecular analysis that showed a mutation in the FGFR3
gene and in a further three analysis of cffDNA extracted from
maternal blood that conﬁrmed the presence of the mutation.
The diagnosis was conﬁrmed in the remaining 26 cases by
postnatal radiology or, in four of these, by molecular analysis
that demonstrated the c.742C>T mutation in three cases and
the c.1948A>G mutation in the fourth. Short limbs occurred
in all cases with bowing of the femora, also a commonly
reported feature, seen in 67% (28/42) of the cases. Frontal
bossing was observed in 80% (24/30 cases where proﬁle
was visualised), cloverleaf skull in 31% (13/42), short
ﬁngers in 52% (16/31 where ﬁngers were examined) and
polyhydramnios in 31% (11/35 cases where amniotic ﬂuid
volume was recorded). Both small narrow chest and short
ribs were described in 95% (35/37) of cases. These ﬁndings
are compatible with descriptions available in the literature
(Table 2), where short, bowed limbs in association with a small
chest and relative macrocephaly are the most frequently
reported ﬁndings. As with our series, there are also occasional
reports of brain anomalies, including ventriculomegaly.
Development of cffDNA assays for TD
There were three cases where maternal blood was taken for
analysis of cffDNA because of suspicious ultrasound
ﬁndings. In one of these families, blood was also taken in a
subsequent pregnancy and cffDNA analysed (Table 3). The
assay for TDI was optimised using gDNA from a chorionic
villus sampling (CVS) sample from a fetus known to have a
c.742C>T transition in the FGFR3 gene, as well as gDNA
from a normal control sample. The amplicon produced by
primer set TDI is 127 bp in size. A normal DNA sample will
be cut by AfeI (producing fragments of 26 and 101 bp) whilst
remaining undigested by both BsiHKAi and DraIII
(Figure 4a). In contrast, a sample that is heterozygous for
the mutation will have one allele that remains uncut by AfeI
but will be digested by BsiHKAi to yield fragments of 27 and
100 bp and by DraIII to yield fragments of 24 and 103 bp.
PCR products from type I TDs or control plasma were
examined for the presence or absence of the AfeI, BsiHKAI and
DraIII restriction sites (Figure 4a). In all control plasmas, the
DNA was digested by AfeI and not by BsiHKAI or DraIII, as
expected. In the two type I TD plasma samples, the maternal
contribution was for the same as that in the normal plasma,
whereas one of the fetal alleles had lost the AfeI restriction site
and gained a BsiHKAI and a DraIII site.
Table 3 Summary of cases where analysis of cffDNA was performed with details of the analysis
Indication Mutation GA cffDNA cffDNA presence conﬁrmed Comments
USS c.742C>T (p.Arg248Cys) 21+1 + n/d Conﬁrmed on amniocytes and PM tissues
USS c.742C>T (p.Arg248Cys) 36+4 + RASSAF1A Conﬁrmed on amniocytes
USS c.1948A>G (p.Lys650Glu) 19 + RASSAF1A Conﬁrmed on skin at PM
Past history c.1948A>G (p.Lys650Glu) 12  SRY Normal live birth
cffDNA, cell-free fetal DNA; GA, gestational age; USS, ultrasound; n/d, not done; PM, post-mortem.
Figure 4 Restriction digest of PCR products for two thanatophoric
dysplasia (TD) mutations. (A) The c.742C>T type I TD mutation was
detected using PCR followed by digestion with AfeI, BsiHKAI and DraIII.
cffDNA from a woman carrying an unaffected fetus is digested with
AfeI (lane 3) but remains uncut using BsiHKAI (lane 4) and DraIII (lane
5); conversely, in an affected fetus, the AfeI site is destroyed, leaving
some of the cffDNA undigested (lane 8), and a BbsI site (lane 9) and
a DraIII site (lane 10) are created. (B) The c.1948A>G mutation
was detected using digestion with the BbsI enzyme and two
different primer sets. In the presence of an unaffected fetus, all
cffDNA is digested by BbsI (lanes 3 and 8), whereas with an
affected fetus, the BbsI restriction site is destroyed, leaving some
of the cffDNA uncut (lanes 5 and 10)
L. S. Chitty et al.420
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The A>T transition at nt 1948 eliminates a BbsI restriction
site. Two sets of PCR primers were designed to amplify this
region of DNA, the ﬁrst producing an amplicon of 120 bp, the
second set producing a 125 bp fragment. A homozygous
unaffected sample will be digested by BbsI, producing
fragments of 32 and 88bp with primers TDII1 and 56 and
69bp with primers TDII2 (Figure 4b). A heterozygous mutation
will cause one of the fetal alleles to lose the restriction site,
resulting in the presence of an additional uncut band. As
before, this assay was optimised on gDNA (data not shown),
then one normal and one TDII plasma sample were examined
for the presence of the mutation. By using both sets of primers,
the control plasma DNA was cut with BbsI, whereas in the
affected sample, there was an extra band representing the
uncut mutant allele.
DISCUSSION
In this study, we have reﬁned the range of sonographic
features seen in TD and provided charts of fetal size, which
clearly help distinguish this lethal condition from other
conditions such as achondroplasia (Figure 3), one of the
conditions most commonly confused with TD.24 We have
demonstrated that limb shortening in TD is sonographically
apparent from as early as 13weeks’ gestation, with minimal
change in size after 20weeks. Similarly, HC is increased
throughout gestation, a feature that is present as early as the
ﬁrst trimester. We recognise that the comparisons are made
with charts of fetuses of normal size that are derived from
cross-sectional data, whereas the TD measurements are a mix
of longitudinal and cross-sectional data. However, we feel that
it is appropriate to compare with these charts as they are the
ones in common use and would be used in clinical practice
to assess measurements of an affected fetus.
Earlier series report that around 40% of osteochondro-
dysplasias are correctly diagnosed by ultrasound in the
prenatal period.6–10,25,26 By using ultrasound scan alone, the
diagnosis of TD was suspected in 86% of the cases in our
cohort. This is consistent with other studies that investigated
the accuracy of prenatal diagnosis of TD using ultrasound
(88% in Schramm et al.,5 70% in Sharony et al.,6 50% in Tretter
et al.,7 40% in Gaffney et al.,8 75% in Doray et al.9 and
approximately 50% in Krakow et al.10).
Published reports suggest that it is possible to accurately
predict that cases presenting with sonographic evidence of a
skeletal dysplasia are likely to be lethal by evaluation of chest
size and conﬁguration.10,27 Others have used a femur length/
AC ratio <0.16 as a sensitive threshold for predicting lethal
skeletal dysplasia.28 In our series, we were able to evaluate this
ratio in 35 cases – these and all TD cases reported in
the literature that included the femur length/AC ratio had a
FL/AC ratio of <0.16. Predicting lethality may be possible
and reliable, but deﬁnitive conﬁrmation of the underlying
pathology is critical for accurate parental counselling with
regard to recurrence risks as well as the management of future
pregnancies. Traditionally, this can be carried out using
molecular analysis of chorionic villi or amniocytes following
invasive testing,11,29 or by postnatal radiology. The differential
diagnosis for TD is broad andwill vary with gestation (Table 4).
In early pregnancy, the main differentials will include other
dominantly inherited conditions such as spondylo-epiphyseal
dysplasia congenita30 but will also include conditions such as
the short-ribbed polydactyly syndromes that are inherited in
an autosomal recessive fashion.4 With the increasing use of
early ultrasound, detection of features suspicious of TD at a
time when a surgical termination of pregnancy is an option
will increase. This management pathway precludes the use
of postnatal radiology for conﬁrmation of diagnosis and
restricts options to molecular analysis following invasive
prenatal testing or analysis of fetal products after termination.
In our experience, many women faced with the diagnosis of
a lethal condition in their pregnancy are reluctant to undergo
invasive diagnostic testing, and many will opt for a surgical
approach to ending the pregnancy if possible. Thus, the
availability of NIPD by analysis of cffDNA in maternal blood
offers the potential for a very useful adjunct to prenatal
diagnosis in this situation, allowing deﬁnitive diagnosis
following a maternal blood sample. Other situations where
NIPD may prove very useful include twin pregnancies where
one twin is normal and the other has features of TD. Here,
conﬁrmation of the diagnosis is useful not just for genetic
counselling but also to inform management without need for
an invasive test that carries a risk to the normal fetus. Finally,
whilst presentation in the third trimester is uncommon
with widespread use of routine second trimester anomaly
scanning, targeted NIPD screening formutations in the FGFR3
gene could readily distinguish TD from achondroplasia. The
recurrence risk for TD in future pregnancies is small and is based
on a gonadal mosaicism risk,31 as this is a lethal dominant
condition. However, parents will often request deﬁnitive
exclusion of a recurrence in future pregnancies. Analysis of
cffDNA in maternal plasma offers an accurate and early
deﬁnitive, but safe, approach to excluding a recurrence. In this
series, we include one case with a past history of TD, who
underwent NIPD at 12weeks’ gestation and received early
conﬁrmation of the absence of the mutation.
The datawe present here have demonstrated thatNIPD for TD
using PCR-RED analysis of cffDNA is possible. Because there are
several mutations causing TD, but few are amenable to
restriction digest, other approaches may be more appropriate.
For example, digital PCR array using allele-speciﬁc real-time
PCR assays can be used to discriminate between wild type and
mutant alleles for up to 12 mutations per fetus, or alternatively,
next generation sequencing may be a useful approach. These
methods will require detailed evaluation but, whichever method
is used, when no mutation is detected, it will be important to
determine the presence20,21 and quantity of cffDNA32 to avoid
reporting false negative results. This will be of particular
relevance when screening for a recurrence in maternal blood
earlier in pregnancy when the levels of cffDNA are lower, 33
thereby increasing the risk of assay failure.
In conclusion, the charts of fetal size for fetuses with TD
presented here will allow for improved sonographic distinction
from other skeletal dysplasias. Deﬁnitive diagnosis of TD is
possible by analysis of cffDNA in maternal plasma. These data
will allow for safer, accurate conﬁrmation of TD and will
inform parental counselling and pregnancy management.
Prenatal diagnosis of thanatophoric dysplasia 421
Prenatal Diagnosis 2013, 33, 416–423 © 2013 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
Ta
bl
e
4
A
id
s
to
th
e
di
ffe
re
nt
ia
ld
ia
gn
os
is
of
th
an
at
op
ho
ric
dy
sp
la
si
a
(T
D
)
TD
A
ch
on
dr
op
la
sia
Je
un
es
as
ph
yx
ia
tin
g
th
or
ac
ic
dy
str
op
hy
SE
D
C
A
ch
on
dr
og
en
es
is
O
IT
yp
e
II
A
/C
O
IT
yp
e
IIB
O
IT
yp
e
III
H
yp
op
ho
sp
ha
ta
sia
M
aj
ew
sk
i
Sa
ld
in
o-
N
oo
na
n
Fe
m
ur
le
ng
th
(<
20
w
ee
ks
)
<
<
3r
d
N
or
m
al
<
3r
d
<
3r
d
<
<
3r
d
<
<
<
3r
d
5t
h
5t
h
<
3r
d
<
3r
d
<
3r
d
Fe
m
ur
le
ng
th
(>
20
w
ee
ks
)
<
<
<
3r
d
N
or
m
al
un
til
>
25
w
ee
ks
w
he
n
gr
ow
th
fa
lls
<
3r
d
<
<
3r
d
<
<
<
3r
d
<
<
<
3r
d
<
5t
h
<
5t
h
<
3r
d
<
3r
d
<
3r
d
H
ea
d
ci
rc
um
fe
re
nc
e
>
95
th
Re
la
tiv
e
m
ac
ro
ce
ph
al
y
N
or
m
al
50
th
–
95
th
Re
la
tiv
el
y
la
rg
e
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
A
bd
om
in
al
ci
rc
um
fe
re
nc
e
N
or
m
al
In
no
rm
al
ra
ng
e
N
or
m
al
N
or
m
al
Re
la
tiv
el
y
la
rg
e
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
N
or
m
al
Fr
on
ta
lb
os
sin
g
+
+









H
yp
om
in
er
al
isa
tio
n
of
ve
rte
br
al
bo
di
es



1s
tt
rim
es
te
r
on
ly
+






Sh
or
tﬁ
ng
er
s/
tri
de
nt
ha
nd
+
+
+
Po
ly
da
ct
yl
y






Po
ly
da
ct
yl
y
Po
ly
da
ct
yl
y
Sm
al
lc
he
st
+/

+/

+
+
(S
ho
rt)
+
+
M
ild

+
+
+
Ri
bs
Sh
or
t

Sh
or
t
N
or
m
al
Sh
or
t
Be
ad
ed
O
cc
as
io
na
l
be
ad
in
g
N
or
m
al
Sh
or
t
Sh
or
t
Po
ly
hy
dr
am
ni
os
+
+/



+
+


+/



H
yp
om
in
er
al
isa
tio
n
of
cr
an
iu
m




+
+
M
ild

+


Lim
b
fra
ct
ur
es





+
+
+
O
fte
n
co
nﬁ
ne
d
to
fe
m
or
a
+/



SE
D
C
,s
po
nd
yl
o-
ep
ip
hy
se
al
dy
sp
la
sia
co
ng
en
ita
l.
L. S. Chitty et al.422
Prenatal Diagnosis 2013, 33, 416–423 © 2013 The Authors. Prenatal Diagnosis published by John Wiley & Sons Ltd.
WHAT’S ALREADY KNOWN ABOUT THIS TOPIC?
• Thanatophoric dysplasia is a lethal skeletal dysplasia amenable to
prenatal diagnosis using fetal ultrasound with molecular conﬁrmation
following an invasive procedure.
WHAT DOES THIS STUDY ADD?
• This study provides data to help distinguish thanatophoric dysplasia from
other skeletal dysplasias and demonstrates the potential for safe, deﬁnitive
molecular conﬁrmation using cell-free fetal DNA in maternal plasma.
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